In 2-3 years after getting injections, the cost discrepancy will be enormous
Siscovick DS, Barringer TA, Fretts AM, et al
Typically, those taking GLP-1 agonists see an improvement in cardiovascular and metabolic health, with improved blood pressure, decreased LDL cholesterol, and lower risk heart disease
It depends on which medicine you get, like Ozempic, Wegovy, or Rybelsus, and on the dose you take
Optometrists should advise their patients that although these medications are conclusively linked to an increased risk of NAION, the overall risk is still extremely low: only about 2.30 per 100,000 people are diagnosed with NAION each year